Alora
NDC Package 51206-310-02
Package Information
Alora is a medication a female hormone (estrogen). Marketed by Ultradent Products, Inc, this product is identified by NDC 51206-310 and is authorized under FDA application M022.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 51206 - Ultradent Products, Inc
- 51206-310 - Alora
- 51206-310-02 - 3 CARTON in 1 PACKAGE, COMBINATION / 1 TUBE in 1 CARTON (51206-310-01) / 113 g in 1 TUBE
- 51206-310 - Alora
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (51206-310). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 51206-310-02 identifies a specific commercial package of 3 carton in 1 package, combination / 1 tube in 1 carton (51206-310-01) / 113 g in 1 tube of Alora Whitening, labeled by Ultradent Products, Inc. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Ultradent Products, Inc on October 01, 2019. The current certification is valid through June 30, 2022.
What are the primary indications for this medication?
This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.
How is this Ultradent Products, Inc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 51206031002. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.